BMY Stock Price Today (October 2026) — Bristol-Myers Squibb Company Analysis & Key Metrics 2026-10-07
Bristol-Myers Squibb Company (BMY) is trading at $59.70, up 0.18% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $66.71 (11.7% upside).
- Volatility is low (21.14% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.70% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
BMY Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Bristol-Myers Squibb Company - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $155.94B
P/E Ratio
Forward P/E: 10.19
Revenue Growth
Year over Year
Analyst Target
+11.7% upside potential
Key Investor Questions About BMY
What investors need to know before buying
Based on current market data, BMY presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 35.42)
- Fundamentals say: Mixed signals (nuanced financial profile)
BMY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BMY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $45.05B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BMY stock traded between $42.52 and $68.64 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.14% annualized volatility and β=0.37, the stock exhibits low sensitivity to market moves—making BMY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitigation Strategy program. Onco360 will handle specialty dispensing and clinical support for eligible patients as ZENBEXUS enters commercial rollout for an underserved group. The selection of Onco360 for ZENBEXUS distribution comes against...
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
New Strong Buy Stocks for September 24th
BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.
Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?
BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is currently trading at $59.70. The RSI (14-day) is at 35.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $66.71 implies 11.7% upside from current levels. Volatility is moderate at 21.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bristol-Myers Squibb Company (BMY): The trailing P/E ratio is 14.12, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.19, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.37, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.87. Price-to-Sales is 2.66. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering BMY, the consensus price target is $66.71. This represents a 11.7% upside from the current price of $59.70. The range spans from a low target of $40.00 to a high target of $82.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a current yield of approximately 4.22%. The annualized dividend rate is $2.51 per share. The payout ratio is 55.3%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Oct 2, 2026.
Key risks for Bristol-Myers Squibb Company (BMY) investors include: 1. Elevated debt levels (debt-to-equity of 2.02x) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bristol-Myers Squibb Company's (BMY) current debt and financial health profile: Total debt stands at $45.05B. The debt-to-equity ratio is 2.02x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.53, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $11.07B in cash and equivalents. Free cash flow is positive at $8.11B, providing a cushion for debt servicing and shareholder returns.